COMMUNIQUÉS West-GlobeNewswire

Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study

11/12/2017 - 16:51

Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN data Results were [...]

Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting

11/12/2017 - 16:45

Encouraging initial anti-leukemic activity with durable responses and acceptable tolerability observed in dose expansion cohort Data supports combination with MGA012 (anti-PD-1) to potentially enhance anti-leukemic [...]

Thetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBD

11/12/2017 - 16:35

BRANFORD, Conn., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing oral, “immuno-resolving” therapies to treat inflammatory bowel disease (IBD), announced [...]

Reporting of transactions with ALK-Abelló A/S' B-shares and associated securities by person closely associated with person discharging managerial responsibly

11/12/2017 - 16:29

Copenhagen, 2017-12-11 16:29 CET (GLOBE NEWSWIRE) -- With reference to company announcement no. 35/2017 and no. 36/2017 regarding offering, pricing and completing of the offering of new shares in ALK-Abelló A/S, company [...]

Novo Nordisk A/S - Share repurchase programme

11/12/2017 - 16:03

Bagsværd, Denmark, 11 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers

11/12/2017 - 16:00

CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of farnesyl transferase [...]

Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting

11/12/2017 - 16:00

ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]

BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting

11/12/2017 - 16:00

CAMBRIDGE, Mass. and BEIJING, China, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]

Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD)

11/12/2017 - 16:00

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, [...]

Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile

11/12/2017 - 16:00

Preclinical Data Shows Potential of eFT226 in B-cell Malignancies Data to be presented at the ASH 59 th Annual Meeting and Exposition SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in [...]

BioStem Technologies Inc. Announces a Pre-Clinical Study of BSEM17-115 at University of Miami

11/12/2017 - 15:43

Pompano Beach, FL, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BSEM” or “Company”), in collaboration with the University of Miami’s Department of Dermatology and Cutaneous Surgery [...]

FRDJ salue la décision de l’ARC de revoir les refus des demandes pour le diabète

11/12/2017 - 15:33

TORONTO, 11 déc. 2017 (GLOBE NEWSWIRE) -- Les plus de 300 000 Canadiens et leur famille qui vivent avec le diabète de type 1 (DT1) au pays se réjouissent de l’annonce faite aujourd’hui du gouvernement du Canada et de l’ [...]

Salvis Lapins Will Remain of Olainfarm’s Management Board

11/12/2017 - 15:20

Olaine, 2017-12-11 15:20 CET (GLOBE NEWSWIRE) -- “I have very strong ties with Olainfarm. They have matured during more than a decade, during which we had our reasons for celebrations and we have coped with quite a few [...]

Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference

11/12/2017 - 15:05

WESTLAKE VILLAGE, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of [...]

Aptevo Therapeutics’ Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples

11/12/2017 - 15:02

New APVO436 Preclinical Data Show Robust T-Cell Engagement and Cytotoxicity in AML Patient Specimens SEATTLE, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO ), a biotechnology company focused [...]

Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium

11/12/2017 - 15:00

Supinoxin enhances the efficacy of immunotherapy in multiple preclinical models Supinoxin shows potent activity against patient-derived triple negative breast cancer (TNBC) tumors in preclinical models Supinoxin is [...]

Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders

11/12/2017 - 15:00

NORCROSS, Ga., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, announced today that the Company will present a corporate [...]

Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura

11/12/2017 - 14:30

HAYWARD, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ) today announced a positive outcome of the pre-specified interim futility analysis for the RESULT Phase 3 clinical study of [...]

ToolGen, Inc. Demonstrates Potential of CRISPR/cas9 Gene Editing to Overcome T-Cell Immunosuppression

11/12/2017 - 14:30

Potential Therapeutic Strategy to Target Tumors that Evade T-Cell Immune Response Data Presented at the 59 th American Society of Hematology Annual Meeting SEOUL, South Korea, Dec. 11, 2017 (GLOBE NEWSWIRE) -- ToolGen, [...]